D'Or Institute for Research and Education (IDOR) played an important role in the phase III LIBRETTO-431 multicenter study, which evaluated the efficacy and safety of selpercatinib compared to control treatment, which consisted of platinum-based chemotherapy associated or not with pembrolizumab (immune checkpoint inhibitor) in non-small cell lung cancer (NSCLC).
Evaluating selpercatinib for the treatment of non-small cell lung cancer medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
IDOR Evaluates Selpercatinib in Non-Small Cell Lung Cancer Study miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.